Key result
Anti-cancer agents, including traditional chemotherapy and newer biological agents, can cause dyspnea through cardiac, pulmonary, and vascular toxicities.
Palliative care professionals must be aware of the diverse mechanisms of anti-cancer agent-induced dyspnea, including cardiac and pulmonary toxicities, to effectively manage these potentially fatal adverse effects.
Answers are grounded in this paper and cite their sources.
May warrant consideration of anti-cancer toxicities in dyspnea evaluation; leaves open targeted palliative trials.
Anti-cancer agents can cause dyspnea through a variety of mechanisms; cardiac toxicity, pulmonary toxicity, and vascular thrombotic events. Toxicity of the anthracyclines and other traditional chemotherapy drugs are well known, but problems associated with the newer biological agents are less well recognized. As palliative chemical therapies are being given to cancer patients even in advanced disease, it is important that palliative care professionals are aware of potential adverse effects that range from deteriorating dyspnea to rapid death. This article summarizes the agents associated with such toxicity, the mechanisms underpinning the effect on dyspnea, and the varying clinical presentations and management.
No takes yet. Share an insight, caveat, or question.
Maraveyas et al. (2011) conducted a review in Anti-cancer agent-induced dyspnea. Anti-cancer agents was evaluated. Anti-cancer agents, including traditional chemotherapy and newer biological agents, can cause dyspnea through cardiac, pulmonary, and vascular toxicities.
Synapse has enriched 10 related papers. Consider them for comparative context: